BCRF Pink Press Winter 2011

Transcription

The breast Cancer Research Foundation
Founded in 1993
Pink Press
®
®
Myra Biblowit, Dr. Larry Norton, Evelyn Lauder and
President Bill Clinton
PHOTO: Julie Skarratt
PHOTO: Rob Rich
winter 2011
Pierce Brosnan and Judy Craymer
BCRF 2010 Awards Luncheon
Honoring
our Super Heroes
BCRF’s Annual Symposium and Awards Luncheon on October 27 was an exceptional occasion for a variety of reasons. Drawing
more than 1,000 guests to The Waldorf=Astoria in New York City, the event raised over $2 million, and the Foundation awarded
$33 million in grants to 172 researchers from around the world. It was especially poignant as the morning Symposium was dedicated to Josie Robertson, a beloved member of the BCRF Board of Directors who passed away in June. Evelyn Lauder described
Mrs. Robertson as “an inspiration” who was fully committed to finding prevention and a cure for breast cancer since day one.
Surprising the audience with his presence, former President Bill Clinton welcomed the guests. “Every time I see a pink ribbon, it
is very personal to me,” said Clinton, who spoke candidly about how breast cancer has impacted his life. As President, Clinton
signed the Breast and Cervical Cancer Prevention and Treatment Act of 2000, which increased healthcare coverage for patients
as a way to prevent families from being driven to bankruptcy because of medical costs. In his private role as the son of a mother
who died from breast cancer, he articulated the all-too-familiar toll that the disease exacts on families. Sharing these intimate
details, Clinton inspired everyone in the audience as to the reasons why supporting research must take center stage in the effort
to prevent and cure breast cancer.
continued on page 3
A Message from Evelyn Lauder, Founder and Chairman
This October, at our annual Symposium and Luncheon, we honored our “Super Heroes”; the 172 brilliant medical scientists from around the world
who are changing the face of breast cancer. BCRF’s Super Heroes continue to gain momentum and are saving more lives each year. They are the
best and the brightest, and it is a privilege to raise funds to support their enormous talent. Since 1993, BCRF has raised over $300 million to support
research. I am so proud that we were able to award $33 million in grants to this year’s group of researchers. They represent 12 countries across the
United States, Canada, Latin America, Europe, the Middle East and Australia.
People often praise me for my work at BCRF, but I truly know that all the praise should be directed to two groups – our
wonderful staff at the Foundation and our Super Heroes: the men and women who dedicate their life’s work to finding
an end to this disease or ensuring that we have ways to prevent breast cancer in the near future. When you talk to these
scientists, you can’t help but feel their energy, their excitement, their enthusiasm, and their commitment to their research
projects. They are our fuel. We are so close to living in a world where breast cancer is obsolete. With your continued
support, our Super Heroes can make this a reality.
Wishing you a healthy and happy 2011.
Evelyn H. Lauder
PHOTO: Wire Image.com
Supporting BCRF means you are supporting the very best science in breast cancer in the world. BCRF continues to be one of the most efficient
organizations—having received 4 stars from Charity Navigator for nine consecutive years, BCRF has outperformed 99% of more than 5,500
evaluated charities. Furthermore, the Foundation is consistently listed as an “A+” charity by The American Institute of Philanthropy.
Dr. Joan Brugge and Anne Keating
Dr. Andrea Richardson,
Jane and Neil Golub
Dr. Michael Press, Joanne Smith;
Drs. Susan Horwitz, Hayley McDaid,
Sofia Merajver and Adrian Harris
Tommy and Dee Hilfiger
Cynthia Lufkin and
Muffie Potter Aston
The breast Cancer Research Foundation®
Dr. Annette Stanton, Kay Krill, Dr. Carol Fabian,
Evelyn Lauder and Dr. Dawn Hershman
UNLESS OTHERWISE NOTED PHOTOS: Julie Skarratt
Perri Peltz, Danielle Ganek and
Gigi Mortimer
PHOTO: Rob Rich
Gail Hilson and
Anne Sitrick
PHOTO: Rob Rich
PHOTO: Rob Rich
Mike Tucci, Dr. Robert Schneider, Myra Biblowit; Drs. Silvia
Formenti and Judy Garber; Evelyn Lauder and Todd Kahn
PHOTO: Rob Rich
winter 2011
2
Myra Biblowit set the stage for The Humanitarian Award, now named in memory of Sandra Taub, daughter of devoted and steadfast supporters of the Foundation, Arlene and Joseph Taub. Actor Pierce Brosnan presented the 2010
Sandra Taub Humanitarian Award to Judy Craymer, the creator and producer
of the global phenomenon Mamma Mia! Describing her as “one of those beautiful women who would change your life forever,” Brosnan recounted the exhilarating experience of working with Craymer – in spite of the fact that she
had dressed him in tights. Craymer has been a staunch supporter of BCRF
since 2001, following a serendipitous meeting with Evelyn Lauder on a transAtlantic flight. Inspired by their meeting, Craymer created the “Rock Chick
Supremo” t-shirt, which is sold at all Mamma Mia! productions world-wide and
has generated over $750,000 for BCRF. Impressing everyone in the audience
with her sincerity in accepting the award, Craymer spoke directly to the BCRF
grantees in the audience. “Life is about second chances, and that is what you
give us. You are, after all, the rock stars of medical science.”
PHOTO: Rob Rich
Mrs. Lauder thanked everyone in the room for supporting our Super Heroes—
the men and women who are working tirelessly to realize a cure for breast
cancer in our lifetime. She then turned the program over to Dr. Larry Norton,
who presented the 2010 Jill Rose Award to Dr. Angela Hartley Brodie.
3
Marshall Rose; Drs. Angela Hartley
Brodie and Larry Norton; and Wendi Rose
The Symposium and Awards Luncheon was made possible by underwriters
Roz and Les Goldstein, Terry and Katie Wheatley of Tough Enough to Wear
Pink, and Evelyn and Leonard Lauder. The Foundation also wishes to thank
Co-Chairmen Roberta Amon, Anne Bass, Betsy Green, Joanne de Guardiola,
Ronnie Heyman, Gail Hilson, Evelyn Lauder, Bonnie Englebardt Lautenberg,
Cynthia Lufkin, Gigi Mortimer, Wendi Rose, and Arlene Taub.
PHOTO: Rob Rich
Alex Robertson and Lizzie Tisch
Jamee Gregory, Audrey Gruss,
Anne Eisenhower Flöttl
Dr. Michael Sporn, Tom Hipwell
and Dr. Karen Liby
Caryn Zucker and Tory Burch
Dr. Kenneth Offit, Arlene Taub and Dr. Walter Willett
PHOTO: Rob Rich
Jenny Paulson and Joanne
de Guardiola
Science
The Complex Role of
Hormones in Breast Cancer Development and Treatment:
A View from the Experts
With an all-star panel consisting of BCRF’s Executive Board of Scientific Advisors and the 2010 Jill Rose Awardee, this year’s
Symposium focused on The Many Faces of Hormones and Breast Cancer: Expert Views of Causation, Treatment and Prevention. The
experts traced the early path of treatments for hormone-receptor-positive breast cancer, which is the most frequently occurring
type of breast cancer, continuing on to new lines of scientific inquiry emphasizing individualized treatment and preventive care.
This signature event brought together a breast cancer brain trust, including 140 of the 172 BCRF 2010-2011 grantees, to help
an overflow audience of more than 500 guests get to the bottom of hormones – specifically estrogen – and breast cancer and
what people can do to minimize risk and maximize treatment options. The scientists reminded the audience that the presence
of estrogen in itself is not a risk factor for breast cancer, but that about 80% of breast cancers express the estrogen receptor,
whose growth is fueled by estrogen.
winter 2011
4
PHOTO: Rob Rich
At the panel’s center was Angela Hartley Brodie, PhD (Professor of Pharmacology and Experimental Therapeutics at the
University of Maryland), recipient of the 2010 Jill Rose Award for Distinguished Scientific Achievement, in recognition of
her seminal research in the development of aromatase inhibitors, drugs that stop the production of estrogen. Joining her on
the panel from BCRF’s Executive Board of Scientific Advisors were BCRF’s Scientific Director, Larry Norton, MD, Director
of Breast Cancer Programs at Memorial Sloan-Kettering Cancer Center; Nancy Davidson, MD, Director of the University of
Pittsburgh Cancer Institute; Peter Greenwald, MD, Dr.PH, Director of the Division of Cancer Prevention and Control at the
National Cancer Institute; and Gabriel Hortobagyi, MD,
Chairman of the Department of Breast Medical Oncology at
the University of Texas, MD Anderson Cancer Center. Clifford
Hudis, MD, BCRF Scientific Advisory Committee Chair and
Chief of Breast Cancer Medicine at Memorial Sloan-Kettering
Cancer Center, moderated the lively presentations.
When Dr. Brodie, this year’s honoree, began her research in
the 1960s, very little was known about the relationship between
estrogen and breast cancer. Scientists knew that there was a
connection; Dr. Hortobagyi provided a historical example
dating to the 1890s, when it was noted that surgical removal
Drs. Clifford Hudis, Angela Hartley Brodie, Gabriel Hortobagyi,
of ovaries of young breast cancer patients seemed to “cure”
Nancy Davidson, Peter Greenwald and Larry Norton
some of these women of the disease. Building on later work
that elucidated more precisely the link between estrogen and breast cancer, Dr. Brodie’s investigations spurred the development
of aromatase inhibitors, used in post-menopausal women with breast cancer to stop the production of estrogen. Thanks to
her work, there are three aromatase inhibitors on the market today and they are used to both treat breast cancer and prevent its
return after surgery. They may even have a role in prevention, and research studies exploring this are underway. Dr. Brodie continues to focus on resistance to the aromatase inhibitors, since as many as one-third of breast cancer patients do not respond to
hormone therapy and a significant percentage of ER+ tumors eventually become less responsive.
Drs. Hortobagyi and Davidson each spoke about their work. The general guideline for treating women with ER+ breast
cancer calls for tamoxifen when they are pre-menopausal and aromatase inhibitors after menopause. This is a good example of
the specificity that researchers have been able to achieve; however, they have not yet reached the ultimate goal of truly individualized therapy which might include patient-specific treatment selection based not only on the characteristics of the tumor but also
on other factors related to the patient as a whole. Dr. Davidson then spoke of the need to address challenges facing survivors who
have to confront not only the possibility of their cancer’s recurrence and metastasis but also the long-term effects of therapeutics,
such as chemo- or radiation therapy. Hormone therapies are typically associated with fewer side effects but studies continue to find
even safer ways to use them.
Dr. Greenwald shared with the audience his expertise on cancer prevention, telling them that “breast cancer prevention starts
with your life habits, including diet and exercise.” He explained that data from the first generation of prevention studies showed
that lifestyle changes, such as weight loss and reduced consumption of alcohol, lower the risk of developing cancer. With respect
to weight, studies have shown that obesity increases estrogen and inflammation levels, the elevation of which exposes women to
greater risk of breast cancer. As far as environmental factors that have been attributed to the incidence of breast cancer,
Dr. Greenwald pointed out that it is very difficult to measure the level of toxins in a population, so direct cause and effect has not
yet been demonstrated.
The Symposium concluded with a lively exchange among the audience, panelists, and many of the BCRF grantees.
Part of the discussion clarified the distinction between hormonal treatment for breast cancer, which works by
blocking or lowering estrogen levels in the body, and hormone replacement therapy (HRT) after menopause, use of
which has fallen off since clinical trials demonstrated that the estrogen in HRT can increase the risk of breast
cancer development. HRT did not provide many of the benefits people thought it would. “Cancer is complex but has
an Achilles’ heel, and it is our job to find its weaknesses and exploit them,” summarized Dr. Norton. “Are there easy
answers? No. Are there hints? Absolutely!”
Research Retreat for Grantees
The enthusiasm at the Symposium matched the energy at the scientific retreat for BCRF researchers that took place the day
before. The annual retreat, sponsored by Muriel Siebert, followed a “think tank” format, and researchers participated in one
of six sessions: Biomarkers; Cancer Stem Cells and Cancer/Stroma Interactions; Therapeutic Targets/Targeted Therapeutics;
Cancer Susceptibility Genes; Molecular Classification, Prognostication and Prediction; and Prevention and Survivorship. In each
group, investigators brainstormed the most important “next steps” in breast cancer research, and then the entire group met to
hear summaries from group moderators. As a take-away to be shared among the participants, Dr. Norton requested that each
researcher submit a sentence describing her or his “Zen wisdom” about the most important research advance discussed, and
another describing the greatest impediment to progress. Responses to date have centered on a few main themes and concerns,
including the as-yet unrealized goal of therapy that is truly personalized, the need to better unify research on the discovery of
new biomarkers for breast cancer, and more recognition of the very broad genetic diversity within individual breast cancers.
This event embodies BCRF’s commitment to encouraging dialogue and fostering collaboration among breast cancer researchers
from all corners of the globe.
Grantees
in the News
In June 2010, Kathryn B. Horwitz, PhD, Distinguished Professor at the University of Colorado School of Medicine, received
the Fred Conrad Koch Award, the highest honor bestowed by The Endocrine Society, in recognition of exceptional contributions to the field. Dr. Horwitz has also been chosen to receive the 10th Rosalind E. Franklin Award for Women in Science from
the National Cancer Institute to be presented in January 2011.
In September, President Cristina Fernandez de Kirchner of Argentina formally launched the National Cancer Institute of
Argentina and appointed Eduardo L. Cazap, MD, PhD, Deputy Director of the Institute. Dr. Cazap is President and
Founder of Latin American & Caribbean Society of Medical Oncology (SLACOM) and President of International Union
Against Cancer.
Silvia C. Formenti, MD was honored at the NYU Cancer Institute Gala on October 5, for her contributions to cancer care
and research. Dr. Formenti is the Sandra and Edward H. Meyer Professor of Radiation Oncology, the Chair of the Department
of Radiation Oncology, and co-leader of the Breast Cancer Research Program at NYU Langone Medical Center.
Two BCRF grantees were elected as new members of the Institute of Medicine (IOM) in October. Charis Eng, MD, PhD,
Professor of Genetics and Chair and founding Director of the Genomic Medicine Institute of the Cleveland Clinic, and
Titia de Lange, PhD, the Leon Hess Professor at The Rockefeller University, joined 63 fellow scientists and five foreign
associates as IOM’s Class of 2010. As the health arm of the National Academy of Sciences, the IOM functions as an
authoritative body advising both decision makers and the public, with the underlying mission of improving human health.
In November, Mary-Claire King, PhD received the Pearl Meister Greengard Prize from
The Rockefeller University for her research which has advanced the science of genetics and
improved medicine for the benefit of humankind. Dr. King also was awarded the 2010 Double
Helix Medal from Cold Spring Harbor Laboratory for her major contributions to understanding the genetics of breast cancer. Sharing the same honor, Evelyn Lauder was recognized for
her efforts in raising aware ness and support for clinical and translational research on breast
cancer at medical institutions across the globe.
On November 18, José Baselga, MD, PhD was awarded the 2010 Queen Sofía Spanish Institute’s Gold Medal, representing
Spain’s leadership in the area of cancer research. Dr. Baselga, Associate Director of the Massachusetts General Hospital
Cancer Center and Professor of Medicine at Harvard Medical School, was previously the Director of the Vall d’Hebron
Institute of Oncology in Barcelona.
5
Q&A
with Dr. Carol Fabian
Professor of Internal Medicine
Kansas Masonic Cancer Research Chair
Director, Breast Cancer Prevention and Survivorship Centers
University of Kansas Medical Center
Kansas City, Kansas
Q: Tell us about yourself as a scientist and how you became interested in breast cancer
research. Did you ever seriously consider another kind of career than that of the sciences?
My interest in science dates back to my early college days. I was first attracted to
psychology, then microbiology, and finally medicine. I never did consider another type of
career other than the sciences.
winter 2011
6
I became interested in breast cancer research during fellowship training in oncology.
Although I was interested in a variety of different types of cancer, I was particularly drawn
to breast cancer because it seemed like so many young women at the time were being
affected by the disease.
Q: What factors have motivated you to continue studying this field?
My interest in risk assessment and prevention research came about 15 years after I started treating cancer patients.
When I completed training in the 70s there was tremendous excitement in oncology. We thought almost every woman
with early breast cancer could be cured with the right combination of adjuvant treatment. That is still the basic premise
of treatment research and we have made tremendous strides in the past 35 years. However, after a decade and a half of
oncology practice, it became very painfully obvious to me that many women who had early breast cancer were not going to be cured despite doing everything “right.” That is, they got their yearly mammograms, the cancer seemed to have
been detected early, and they received aggressive adjuvant therapy; yet, many still relapsed and died. In addition, many
women who did appear to be cured had lingering side effects which reduced their quality of life. Prevention of breast
cancer by blocking or reversing precancerous changes with medication rather than waiting for it to happen seemed to
make sense.
The early days (circa 1990) of working in risk assessment and prevention were a little tough. We needed tools to predict
who was at highest short-term risk and who was likely to respond to therapy. My team and I refined a fine-needle aspiration (FNA) technique so that we were able to get representative breast tissue, kind of like a “pap smear” for the breast
tissue, to test for signs of precancerous change and, thereby enabling doctors to more accurately assess a person’s
short-term risk of developing breast cancer and target appropriate women for prevention treatment. While this made
infinite sense to us, it did not to most others. Conventional wisdom was that you did not put a needle into a woman’s
breast unless you had a lump or other abnormality to aim at.
We were, however, eventually able to show that for women who had a family history of breast cancer or who had a prior
precancerous biopsy, random sampling of her breast tissue by FNA could more accurately predict short-term risk than
by using risk models alone. Once we were able to demonstrate that we could better predict which women were at high
short-term risk of developing breast cancer, the challenge became to apply clinical prevention interventions. Concerns
over possible side effects keep many women from using standard prevention options such as tamoxifen, or raloxi fene,
or even prophylactic surgery. Consequently, we began early-phase testing of interventions with fewer effects using the
FNA technique to sample tissue before and after the intervention. One of our goals was to make the aspirations as
comfortable as possible so that the patients would come back and get them again.
Q: Briefly describe your BCRF-funded research project. What are some laboratory and/or clinical experiences that
inspired your work? What are your primary goals for this research?
My first BCRF project, which is still ongoing, is developing new tissue-based biomarkers for women who are at increased
risk of breast cancer but whose tissue samples obtained by FNA did not have a high growth (or proliferation) rate even
though it might have some atypical looking cells. These women are primarily post-menopausal, overweight women who
are not on hormone replacement therapy. Although these women have very low proliferation rate in their benign tissue,
they can still develop cancer over time. Part of the reason is that inflammatory cytokines and adipokines may promote
survival and more aggressive behavior of atypical cells.
In conjunction with Dr. Stephen Hursting, another BCRF researcher at the University of Texas, we started looking at
inflammatory markers in breast tissue and blood. We found that we could measure the inflammation markers reliably in
the breast tissue. We are currently trying to make sure that in the absence of an intervention (i.e., drugs or weight loss,
etc.) that these markers are still consistently expressed over time.
Building on the first two years of our BCRF research, we have developed new pilot trials (one of which is funded by
BCRF) using high-dose omega 3 fatty acids and have proposed trials using energy balance interventions.
Q: How close are we to preventing and curing all forms of breast cancer?
At the time I completed my training in the mid-1970’s, 40% or more of the women who developed breast cancer were
dying from it. Now fewer than 20% of women, who were undergoing regular screening at the time their breast cancer
was discovered, will ultimately die of their disease. Although that figure is still too high, the change over 35 years is
amazing.
For prevention, we have identified drugs that will reduce by half the 5-to-10 year risk of developing breast cancer. The
problem is few risk-eligible women will take them. So, I think we have to look at multiple prevention strategies,
emphasizing interventions likely to be attractive to women at different stages of their life. The emphasis should be on
things that women can do themselves which do not require extensive medical monitoring. These interventions ideally
should make them look better and feel better (like diet and exercise). We also need to give a map and a toolbox such
that they can accomplish their goals. I see prevention going in that direction.
Q: In your opinion, how has BCRF impacted breast cancer research?
BCRF has impacted breast cancer research in at least two very important ways. One is that the organization stimulates
cross-collaboration by bringing together established breast cancer researchers from various fields. The collaboration
between Dr. Hursting’s and my group is an example. BCRF is also unique in that it supplies funds needed to develop the
clinical and translational tools and the preliminary data needed to perform research. Having the tools and pilot data
accelerates the pace of breast cancer research. Read the entire Q&A on www.bcrfcure.org.
BCRF Hosts Conference in Israel on Inherited
Breast and Ovarian Cancer
On November 18 and 19, BCRF co-hosted its first international scientific meeting, a symposium in
Tel Aviv, on Clinical Dilemmas in Management of Breast and Ovarian Cancer in BRCA Carriers. BCRF’s
participation was made possible by a contribution from Advisory Board member Roslyn Goldstein
and her husband, Les. Chaired by BCRF Scientific Director, Larry Norton, MD, the conference
was attended by more than 150 medical oncologists, surgeons, radiation oncologists and other
medical professionals from the Mideast, Europe, Australia and North America; session chairs
included BCRF grantees Drs. Judy Garber (Boston) and Fatima Cardoso (Lisbon), and presenters Dr. Judy Garber
included Drs. Ephrat Levy-Lahad (Jerusalem) and Moein Kanaan (Palestinian Authority).
In her keynote, BCRF grantee Mary-Claire King, PhD (Seattle) credited BCRF support
for studies conducted jointly in the US, Israel and the Palestinian Authority, as
responsible for the creation of a data pool to sequence all critical genes involved in
breast cancer development and to identify mutations known to be deleterious. She cited
the complexity of the challenge to unravel the genetic basis of the disease: while there
are three known mutations of Ashkenazi origin, there are 1,000 known mutations on
BRCA1 and an equal number on BRCA2.
Drs. Fatima Cardoso, Mary-Claire
The content of the presentations reflected the collaborative spirit of BCRF research.
King, Larry Norton; Peg
Drs. Levy-Lahad and Kanaan described their joint efforts with Dr. King to determine
Mastrianni; Drs. Suheir
the genetic basis of inherited predisposition to breast cancer in the Palestinian Arab
Lolas-Hamame and Ephrat Levy-Lahad
population, and to create the infrastructure for providing cancer genetics services to
these women. Dr. Garber provided an overview of the search for new treatments that can be used as chemopreventive agents
for individuals at high risk. She cited work by BCRF grantees at Dartmouth, Drs. Michael Sporn and Karen Liby, who have
shown in the laboratory that PARP inhibitors have potential for use in prevention. In closing the meeting, Dr. Norton said that
breast cancer research is “a model for collaborative effort; there are relatively few areas where there is such integration between
laboratory science and clinical practice.” Highlights from the conference are on www.bcrfcure.org
2011 Unsung Hero Needed
On April 14, the Unsung Hero Award, established by Roz and Les Goldstein, will be presented at the
NYC Hot Pink Party to a special individual who has been a source of support, hope,
humor, strength and comfort to a woman facing breast cancer.
Send nominations to Myra Biblowit by February 1: [email protected] or 646-497-2601
7
2010 - 2011 Grantees
Albert Einstein College of Medicine
New York, NY
Cold Spring Harbor Laboratory
Cold Spring, NY
Jill Bargonetti, PhD
Made possible by Estée Lauder
Memorial Sloan-Kettering Cancer Center
New York, NY
Rachel Hazan, PhD
The First Step Award, made possible by
QVC & Fashion Footwear Charitable
Foundation
Michael H. Wigler, PhD
The Play for P.I.N.K. Award
Indiana University School of Medicine
Indianapolis, IN
Robert Benezra, PhD
Columbia University Mailman
School of Public Health
New York, NY
Susan E. Clare, MD, PhD
Made Possible by ULTA
Monica N. Fornier, MD
Regina M. Santella, PhD
Made possible by Aveda
Kathy D. Miller, MD
Made possible by Ann Taylor Stores
Corporation
Alan N. Houghton, MD
The Peter Jay Sharp Foundation Award
Thomas E. Rohan, MD, PhD
Mary Beth Terry, PhD
Made possible by Aveda
George W. Sledge, MD
Arizona State University
The Biodesign Institute
Tempe, AZ
Columbia University Medical Center
New York, NY
Susan B. Horwitz, PhD
Made possible by Delta Air Lines, Inc.
Joshua LaBaer, MD, PhD
Baylor College of Medicine
Houston, TX
C. Kent Osborne, MD
Rachel Schiff, PhD
Beth Israel Deaconess Medical Center/
Harvard Medical School
Boston, MA
Lewis C. Cantley, PhD
Dawn Hershman, MD, MS
Corporation
Dana-Farber Cancer Institute/Harvard
Medical School
Boston, MA
Judy E. Garber, MD, MPH
The Coach Award
Anna Maria Storniolo, MD
Made possible by ULTA
INSERM, Centre René Huguenin
Paris, France
Rosette Lidereau, PhD
Institut Jules Bordet
Brussels, Belgium
Hedvig Hricak, MD, PhD
Made possible by Macy’s
Clifford Hudis, MD
Johanna A. Joyce, PhD
Philip O. Livingston, MD
Shanu Modi, MD
ASCO Cancer Foundation
Larry Norton, MD
Martine J. Piccart-Gebhart, MD, PhD The Peter Jay Sharp Foundation Award
Breast International Group/TRANSBIG The First Step Award, made possible by QVC
Made possible by Roche
& Fashion Footwear Charitable Foundation
J. Dirk Iglehart, MD
Made possible by Price Chopper
William G. Kaelin, Jr., MD
Stuart J. Schnitt, MD
Nancy U. Lin, MD
The Housewares Charity Foundation Award The Play for P.I.N.K. Award
Nadine M. Tung, MD
David M. Livingston, MD
The Housewares Charity Foundation Award
Ursula A. Matulonis, MD
Bethlehem University
Bethlehem, Palestinian Authority
Kornelia Polyak, MD, PhD
Moein Kanaan, PhD
Brigham & Women’s Hospital/Harvard
Medical School
Boston, MA
Andrea L. Richardson, MD, PhD
Made possible by Price Chopper
Zhigang Charles Wang, MD, PhD
PHOTO: Rob Rich
winter 2011
8
Hayley McDaid, PhD
Teresa Gilewski, MD
Ross Berkowitz, MD
Dartmouth Medical School
Hanover, NH
Christos Sotiriou, MD, PhD
Monica Bertagnolli, MD
On behalf of Cancer and
Leukemia Group B
Karen T. Liby, PhD
Made possible by Nestlé Pure Life
Institute of Cancer Research UK
London, UK
Michael B. Sporn, MD
Made possible by Nestlé Pure Life
Alan Ashworth, BSc, PhD, FRS
Made possible by Hard Rock International Neal Rosen, MD, PhD
The Joseph and Arlene Taub Foundation
International Breast Cancer Research
Award
Foundation
Columbus, OH
Charles L. Sawyers, MD
Cancer Institute of New Jersey/
University of Medicine & Dentistry of
New Jersey
New Brunswick, NJ
Duke University
Durham, NC
Bruce G. Haffty, MD
The Play for P.I.N.K Award
John A. Olson, Jr., MD, PhD
On behalf of ACOSOG
Kim Hirshfield, MD, PhD
David Ota, MD
On behalf of ASOCOG
Arnold J. Levine, PhD
The Institute for Advanced Study
CHS National Cancer Control Center
Carmel Medical Center
Haifa, Israel
Gad Rennert, MD, PhD
Champalimaud Cancer Center
Lisbon, Portugal
Fatima Cardoso, MD
Breast International Group/NABCG
Children’s Hospital/Harvard Medical
School
Boston, MA
Emory University on behalf of
NABCG/Breast International Group
Atlanta, GA
William C. Wood, MD
Made possible by Genentech
Boston, MA
Marsha Moses, PhD
Made possible by Clinique
Joan S. Brugge, PhD
Made possible by Bloomingdale’s
Zoltan Szallasi, MD
Harvard School of Public Health
Boston, MA
Cleveland Clinic
Cleveland, OH
The Methodist Hospital Research Institute
Houston, TX
Johns Hopkins Bloomberg School of
Public Health
Baltimore, MD
Jenny Chang, MD
Johns Hopkins University
School of Medicine
Baltimore, MD
Pamela J. Goodwin, MD, MSc, FRCPC
Mount Sinai Hospital
University of Toronto
Kala Visvanathan, MBBS, FRACP, MHS Toronto, Ontario, Canada
Mount Sinai School of Medicine
New York, NY
Stuart A. Aaronson, MD
Vered Stearns, MD
Made possible by The Estée Lauder East
Coast Field
National Surgical Adjuvant Breast and
Bowel Project (NSABP)
Antonio C. Wolff, MD
Pittsburgh, PA
Translational Breast Cancer Research
Consortium (TBCRC)
Soonmyung Paik, MD
Richard C. Zellars, MD
Mayo Clinic: Rochester, MN and
Jacksonville, FL
Debra L. Barton, RN, PhD, AOCN
Walter C. Willett, MD, Dr.PH
Made possible by Wilson Sporting Goods Fergus J. Couch, PhD
Charis Eng, MD, PhD, FACP
On behalf of CIMBA
Hospital of Prato
Coalition of Cancer Cooperative Groups Istituto Toscano Tumori
James N. Ingle, MD
Eastern Cooperative Oncology Group
Prato, Italy
Philadelphia, PA
Angelo Di Leo, MD, PhD
Charles L. Loprinzi, MD
Robert L. Comis, MD
Made possible by Pfizer, Inc.
Hunter College
Edith A. Perez, MD
City University of New York
New York, NY
Mark E. Robson, MD
The Sandra Taub Memorial Award
Richard R. Love, MD, MS
Ohio State University
Fred Hutchinson Cancer Research Center
Seattle, WA
Ben Ho Park, MD, PhD
Peggy L. Porter, MD
On behalf of Southwest Oncology
Group
Kenneth Offit, MD, MPH
The Sandra Taub Memorial Award
Northwestern University
Feinberg School of Medicine
Chicago, IL
Charles Clevenger, MD, PhD
American Association for Cancer Research
Vincent L. Cryns, MD
William J. Gradishar, MD, FACP
NYU School of Medicine
New York, NY
Silvia Formenti, MD
The Coach Award
Robert J. Schneider, PhD
The Coach Award
Ohio State University
Columbus, OH
Thomas Jefferson University
Kimmel Cancer Center
Philadelphia, PA
Andrew A. Quong, PhD
Electra D. Paskett, PhD
Tufts University School of Medicine
Boston, MA
Queen’s University
Kingston, Ontario, Canada
Charlotte Kuperwasser, PhD
Made possible by Saks Fifth Avenue
Lois Shepherd, MDCM, FRCP(C)
On behalf of NCIC Clinical Trials Group
University of California
Irvine, CA
The Rockefeller University
New York, NY
Eva Y.-H. P. Lee, PhD
Titia de Lange, PhD
Made possible by Bloomingdale’s
Jonsson Comprehensive Cancer Center
Los Angeles, CA
Paul M. Nurse, PhD
Patricia A. Ganz, MD
Made possible by Estée Lauder
Roswell Park Cancer Institute
Buffalo, NY
Christine B. Ambrosone, PhD
Made possible by Prime Retail
Royal Marsden Hospital and
Institute of Cancer Research
London, UK
Mitch Dowsett, PhD, BSc
The Elizabeth Hurley Award
Mary Sehl, MD, PHD
Annette L. Stanton, PhD
Corporation
University of Kansas Medical Center
Kansas City, KS
University of Sydney
Sydney, Australia
Carol J. Fabian, MD
Corporation
Janette Vardy, MD, FRACP, PhD
University of Miami
Miami, FL
Tan A. Ince, MD, PhD
Miller School of Medicine
Marc E. Lippman, MD
Miller School of Medicine
San Francisco, CA
Geoffrey M. Wahl, PhD
Laura J. Esserman, MD, MBA
Sarah Lawrence College
Bronxville, NY
Shelley Hwang, MD, MPH
On behalf of Cancer and
Leukemia Group B
Joan H. Marks, MS
New York Breast Cancer Study
Shaare Zedek Medical Center
Jerusalem, Israel
Ephrat Levy-Lahad, MD
Sir Mortimer B. Davis – Jewish General
Hospital/McGill University
Montreal, Quebec, Canada
Isabel Bedrosian, MD
Mien-Chie Hung, PhD
Kelly K. Hunt, MD, FACS
On behalf of ACOSOG
Shaomeng Wang, PhD
John Mendelsohn, MD
Stephen J. Weiss, MD
Gordon B. Mills, MD, PhD
Max S. Wicha, MD
Lajos Pusztai, MD, D.Phil
University of Newcastle, on behalf of
Australian New Zealand Breast Cancer
Trials Group, Australia
W. Fraser Symmans, MD
University of North Carolina
Lineberger Comprehensive Cancer
Center
Chapel Hill, NC
Salk Institute for Biological Studies
La Jolla, CA
University of Texas
MD Anderson Cancer Center
Houston, TX
James M. Rae, PhD
John Forbes, MB, BS
Barbara A. Parker, MD
Stephen D. Hursting, PhD, MPH
Powel H. Brown, MD, PhD
Joyce Slingerland, MD, PhD, FRCP(C)
Braman Family Breast Cancer Institute
Francisco J. Esteva, MD, PhD
Zhen Fan, MD
University of Michigan
Ann Arbor, MI
Sharon Giordano, MD, MPH
Daniel F. Hayes, MD
Ana Maria Gonzalez-Angulo, MD, MSc
Made possible by Eisai Oncology
Group
Sofia D. Merajver, MD, PhD
Gabriel N. Hortobagyi, MD, FACP
Rebecca and John Moores Cancer Center Lori J. Pierce, MD
San Diego, CA
Made possible by ULTA
Ian E. Smith, MD, FRCP, FRCPE
The Elizabeth Hurley Award
University of Texas
Austin, TX
Lisa A. Carey, MD
Made possible by Saks Fifth Avenue
University of Washington
Seattle, WA
Julie R. Gralow, MD
Group
Mary-Claire King, PhD
New York Breast Cancer Study
Vall d’Hebron Institute of Oncology
H. Shelton Earp, MD
Barcelona, Spain
Made possible by The Estée Lauder Field
Joaquín Arribas, PhD
Hyman B. Muss, MD
José Baselga, MD
Charles M. Perou, PhD
Massachusetts General Hospital
Made possible by Susan Hertog
University of Oxford
Oxford, UK
Hope S. Rugo, MD
Adrian Harris, MD, D.Phil
The Housewares Charity Foundation Award Cancer Research UK
Made possible by Delta Air Lines, Inc
Laura J. van ‘t Veer, PhD
University of Pennsylvania
University of Cambridge
Abramson Cancer Center
Cambridge, UK
Philadelphia, PA
Sir Bruce A. J. Ponder, PhD, FRCP, FRS Lewis A. Chodosh, MD, PhD
Cancer Research UK
Susan M. Domchek, MD
University of Chicago Medical Center
Wilson H. Miller, MD, PhD
Made possible by Hard Rock International
American Association for Cancer Research Chicago, IL
Mark I. Greene, MD, PhD, FRCP
Latin American and Caribbean Society of Funmi I. Olopade, MB, BS, FACP
Medical Oncology (SLACOM)
Buenos Aires, Argentina
Katherine L. Nathanson, MD
Monika Burness, MD
Eduardo Cazap, MD
Robert H. Vonderheide, MD, D.Phil
The Hirschhorn Award
Made possible by Hard Rock International
Stanford University School of Medicine
University of Colorado
Stanford, CA
University of Pittsburgh Cancer Center
Health Sciences Center
Pittsburgh, PA
Denver, CO
Michael F. Clarke, MD
Nancy E. Davidson, MD
Kathryn B. Horwitz, PhD
James M. Ford, MD
The Pink Promises Award in memory of
Made possible by Genentech
University of Edinburgh
Patricia L. Hansen
Edinburgh, Scotland
Shannon Puhalla, MD
Shaveta Vinayak, MD
John Bartlett, PhD
Breast International Group/NABCG
University of Southern California
Tel Aviv University
Norris Comprehensive Cancer Center
University of Illinois at Urbana-Champaign Los Angeles, CA
Sackler School of Medicine
Urbana, IL
Tel Aviv, Israel
Michael F. Press, MD, PhD
Benita S. Katzenellenbogen, PhD
Ilan Tsarfaty, PhD
Van Andel Research Institute
Grand Rapids, MI
George F. Vande Woude, PhD
Vanderbilt University School of Medicine
Nashville, TN
Carlos L. Arteaga, MD
The von Mandl Family Award
Washington University School of Medicine
St. Louis, MO
D. Craig Allred, MD
Graham A. Colditz, MD, Dr.PH
Matthew J. Ellis, MD, PhD
On behalf of ACOSOG
Weill Medical College of Cornell University
New York, NY
Andrew J. Dannenberg, MD
Whitehead Institute for Biomedical
Research
Cambridge, MA
Robert A. Weinberg, PhD
Yale University School of Medicine
New Haven, CT
Lyndsay N. Harris, MD
9
Elizabeth Hurley Researchers
Announced at Winfield House
On October 18, at a reception hosted by U.S. Ambassador Louis Susman
and Mrs. Marjorie Susman at Winfield House in London, The Breast
Cancer Research Foundation honored Elizabeth Hurley for spreading the
message globally about the urgency of funding research and also honored
five BCRF-funded United Kingdom-based researchers for their stellar
work. The first annual Elizabeth Hurley Researcher Award was bestowed
upon the team of Drs. Ian Smith and Mitch Dowsett (Royal Marsden
Hospital/Institute of Cancer Research, London). Also in attendance were
Dr. Alan Ashworth (Institute of Cancer Research), Dr. Adrian Harris
(Oxford University), and Sir Bruce Ponder (Cambridge University).
10
winter 2011
A dinner at Bar Boulud London, underwritten by LEVIEV, immediately
followed to celebrate the great science being conducted in the UK with
BCRF’s support. To date, BCRF has invested nearly $4 million in breast
cancer research based in the UK, with nearly $1 million in 2010 alone.
PHOTOS: Richard Lewis
Photos (top to bottom): Dr. Mitch Dowsett, Elizabeth Hurley and Dr. Ian
Smith; Elizabeth Hurley, David and Lisa Klein; Ambassador Louis Susman
and Marjorie Susman
The inaugural Hudson BCRF Golf Classic at Liberty National in NJ on July 12, raised
over $525,000. After a sunny day of golf, guests enjoyed a cocktail reception with a
special viewing of Michael Fux’s private luxury car collection. Celebrity golfers
included sports stars Dan Marino, Jason Taylor, and Alonzo Mourning. Special thanks
to Co-Chairs William Lauder and Paul Fireman, along with the support of major
sponsors Hudson, The Paul & Phyllis Fireman Charitable Foundation, William Lauder,
American Express, Cartier, Rolls-Royce, and The Michael Fux Foundation.
Photos (top to bottom): Dan Marino, Peter Kim, William Lauder, Paul Fireman and
Michael Fux; Ida Rothbaum, Mark Shirvan, Scott Tesser and Joe Rosen
Westchester Luncheon
For the fifth year, BCRF Advisory Board member Shelly Kivell, and Co-Chairs Ellen Brown, Debra Ezratty, Sheryl Kaye and
Kim Meyers, organized a Luncheon at Fenway Golf Club in Scarsdale, NY, raising more than $180,000 from over 200 guests.
BCRF Scientific Advisory Committee Chairman, Dr. Clifford Hudis, gave an overview of Breast Cancer: Progress and Promise that
began with a historical perspective of biomedical research funding in the U.S. He made the point that the Foundation’s grants
program is akin to the MacArthur Foundation’s “genius awards” in that BCRF’s Scientific Advisors seek out the most talented
investigators with creative ideas and they are given the freedom to pursue their ideas
with minimum bureaucracy. In Dr. Hudis’s words, “there is no other grants program
like it” and BCRF-funded scientists have played a role in every important advance in
breast cancer research since 1993.
He told the audience that, while more targeted therapies for breast cancer and more
precise measures of risk reduction are needed, it is important to remember that
there has been steady progress. Breast cancer mortality rates have been falling since
1990, in a longer-living population that is more prone to being overweight. Many
large-scale studies are underway to identify better and more effective treatments and
improve quality of life for breast cancer survivors.
Front row L-R: Debra Ezratty, Kim Meyers, Dr. Clifford Hudis, Evelyn Lauder and Myra Biblowit
Back row L-R: Sheryl Kaye, Shelly Kivell, Ellen Brown
PHOTOS: Michael Blanchard
Hudson BCRF Golf Classic
PHOTOS: Rob Rich
Pink Promises
On October 1, BCRF kicked off breast cancer awareness month with the inaugural Pink
Promises benefit at Crest Hollow Country
Club in Woodbury, NY. BCRF Advisory
Board member Stephanie Ginsberg served as
event Co-Chair along with her husband Ian,
President of C.O. Bigelow. Over 950 guests
attended this sold-out event, which featured
unique auction items, raffle prizes, and fabulous
cocktails donated by Mike’s Hard Lemonade.
The ballroom was adorned with sequin overlays and diamond encrusted centerpieces, in keeping with the evening’s Denim and Diamonds theme. The Mistress of
Ceremonies, LXTV anchor Sara Gore, introduced Stephanie. Stephanie spoke
lovingly about her sister Betsy, who has been battling triple negative breast cancer
for the past five years and is the motivation behind the Ginsbergs’ personal
commitment to Pink Promises—“to raise significant funds…so we may all see
a cure in our lifetime.” Then, Honorary Chairman Evelyn Lauder expressed her
enthusiasm and utmost gratitude for the remarkable turnout from the Long Island community. BCRF grantee and keynote
speaker Dr. Robert Benezra of Memorial-Sloan Kettering Cancer Center, shared a few words regarding his research on breast
tumor growth, angiogenesis, and metastasis that is made possible through BCRF funding. The excitement swelled when popular
appraiser and host of PBS’s History Detectives, Elyse Luray, conducted the live auction, and pop singer Matisse ended the night
on a high note with her live performance.
Pink Promises was a huge success, raising over $850,000, demonstrating Long Island’s strong commitment to finding a cure.
The event was made possible by premier underwriters C.O. Bigelow, The Buller Family Foundation and Marjam Supply
Company, along with lead underwriters BNY Mellon and The Estée Lauder Companies Inc. Special thanks to sponsors
Americana Manhasset, Duffy & Duffy, Sharon and Rich Greenstein, the Jaffee Family, Perfumania, and Tanger Outlet Centers.
Sincere thanks to the wonderful Host Committee for their hours of dedication.
Photos (top to bottom): Rita & Frank Castagna and Evelyn Lauder; Wendy, Alec, Ian, Stephanie and Reed Ginsberg; Sarah & Mark Buller
and Cherie & James Buller
PHOTO: Julie Skarratt
Letter from our President
This year, I am proud to report that BCRF is awarding grants totaling $33 million to 172
researchers from 12 countries around the world. Those are big dollars and you may ask, what
is that investment yielding in 2011? What are the most promising opportunities where our
funding can make a material difference in the lives of women, both in surviving the disease
and preventing it altogether? BCRF’s grantmaking is organized around two main themes:
Finding the Cause—whether that means inherited risk factors, environmental factors, or even
when good cells go bad; and Finding the Cure—endeavors such as the development of
vaccines; the ability to assess risk for breast cancer development, and also for recurrence; the creation of new targeted
therapies; and empowering breast cancer survivors to lead the
healthiest possible lives on their road to complete recovery.
Over the past 16-plus years, BCRF’s grantees have been responsible for some of the most important breakthroughs to
date in breast cancer research. They are truly the “who’s who” of breast cancer research. Whenever a new advance is
reported, you will see a BCRF grantee’s name. Your generous support is what has been driving and leveraging incredible
scientific progress and hope. Thank you for enabling BCRF’s army of brilliant minds to take on the resolution of breast
cancer through multi-faceted approaches. We hope that we can continue to count on your support as we push forward
towards our goal of eradicating breast cancer in our lifetime.
Sincerely,
Myra J. Biblowit
11
12
winter 2011
2010: Play for P.I.N.K. Reaches New Heights
On October 27, Play for P.I.N.K.’s (PFP) Board proudly presented a record-breaking $3.25 million check to Evelyn Lauder and
The Breast Cancer Research Foundation, bringing its cumulative contribution to $22 million! Representatives from Bloomberg
and The Estée Lauder Companies joined the PFP board for this special moment. Honored guests included many of the PFPfunded researchers; Dr. Larry Norton, BCRF Scientific Director and Chairman of the BCRF Executive Board of Scientific
Advisors; and Dr. Clifford Hudis, Chairman of the BCRF Scientific Advisory Committee.
This amazing donation was made possible by an unparalleled number of participants with an increase in both clubs and events.
More than 220 clubs in over twenty-four states got behind PFP this year.
This phenomenal growth would not be possible without our dedicated board, chairwomen, participants, and of course our
generous sponsors. Bloomberg, our title sponsor, underwrites all of the expenses of PFP, enabling 100% of the proceeds to be
donated to BCRF. The Estée Lauder Companies and Wilson Sporting Goods support PFP through their contribution of gifts
and merchandise.
We thank you for your tremendous P.I.N.K. support and look forward to another successful year in 2011!
Think P.I.N.K. Be in the know. Visit www.playforpink.org or call me at 646-497-2605 to find out about ongoing happenings,
how to get involved, or to make a donation.
Sincerely,
Stephanie Hamburger
Director, Play for P.I.N.K.
Delta “Taking Flight for the Fight”
Led by Delta CEO Richard Anderson on September 30, 100 Delta
employees who are breast cancer survivors, flew in the new pink Boeing 767
from Atlanta to Detroit to Minneapolis to inaugurate Delta’s annual breast
cancer program to support BCRF. In addition to donating proceeds from
onboard “pink” sales, Delta had a virtual lemonade stand on Facebook and
donated SkyMiles to BCRF when customers downloaded the Delta iPhone
application. In its sixth year, Delta and its dedicated employees have helped raise over $2.5 million cumulatively for BCRF and
are currently supporting four research projects around the world.
Ann Taylor and LOFT
Continue to Raise the Philanthropic Bar
Ann Taylor Stores Corporation, under the leadership of CEO Kay Krill, raised an unprecedented $2.6 million for BCRF through their ANN Cares® Card and LOFT Cares® Card
programs and products this October. This year’s record-breaking contribution represents an
increase of more than 120% over the previous year and a cumulative donation of more than
$6.4 million to BCRF. In 2010-11, Ann Taylor Stores Corporation is supporting four research
projects: Dr. Kathy Miller from the Indiana University School of Medicine, Dr. Annette
Stanton from UCLA, Dr. Carol Fabian from the University
of Kansas, and Dr. Dawn Hershman from Columbia
University. The 2010 donation will fund ten BCRF
research projects in 2011-2012.
13
Photo: Kara Ross, Myra Biblowit, Deborah Cavanagh, Robin
Renzi and Gary Muto
Bloomingdale’s Pink Campaign
Bloomingdale’s Pink Campaign included a variety of products from The Big Pink Umbrella (designed by
BCRF Advisory Board member Marisa Acocella Marchetto) to The Little Pink Card, the “Give Pink, Get
More” program, and the famous Little Pink Boutique. The 2010 Pink Campaign raised a phenomenal
$1.3 million for BCRF, bringing the retailer’s total donation to over $3 million. Currently, Bloomingdale’s is
supporting the research of Dr. Titia de Lange of The Rockefeller University in New York City and
Dr. Joan Brugge of Harvard Medical School in Boston.
Photos: Evelyn Lauder and Elizabeth Hurley pose with bloggers;Howard Kreitzman,Francine Klein and Elizabeth
Hurley
The Estée Lauder Companies’
2010 Breast Cancer Awareness Campaign
Every October, The Estée Lauder Companies unfolds its Breast Cancer Awareness (BCA) campaign.
The company and employees sponsor a series of
awareness and fundraising programs with the goal
of informing millions of people each year about
the importance of breast health and early detection
and to raise funds for BCRF.
A cornerstone of the BCA campaign is the Estée
Lauder Companies’ Global Landmark Illumination
Initiative. In its 11th Anniversary, more than 200 famous buildings, monuments, and
landmarks were illuminated in glowing pink lights to stand as international symbols of
hope to empower and enlighten millions of women everywhere. The initiative launched
with 38 global landmarks lit pink within 24 hours, achieving a new Guinness World
Record, “Most Landmarks Illuminated for a Cause in 24 Hours.”
Photos: The Estée Lauder Companies’ Sale-A-Bration volunteers; The Estée Lauder brand’s
check presentation to Evelyn Lauder and BCRF; William Lauder and Rich Lehrer at Estée
Lauder golf outing
PHOTOS: Wire Image.com
On September 29, many influential bloggers attended the kick-off for Bloomingdale’s
Pink Campaign and The Estée Lauder Companies’ 2010 Breast Cancer Awareness
Campaign at Bloomingdale’s flagship 59th Street store in NYC. Evelyn Lauder and Estée
Lauder spokesmodel Elizabeth Hurley addressed an eager crowd,
then signed specially designed Estée Lauder Pink Ribbon products
benefiting BCRF.
community fundraisers
Cross Country for the Cure: Fairbury, IL
The Prairie Central Cross Country team held a “Cross Country for the Cure” run on
October 26. The team started on Fairbury’s main street and ran around town until
exhausted. Each member of the team ran for at least 80 minutes, and some ran for a
full 120 minutes! The team members raised funds from the community, either as a flat
donation or pledging a dollar amount per minute ran. The team raised over $2,600 and
are excited to turn this into an annual event.
14
winter 2011
F Stop Breast Cancer: www.fstopbreastcancer.com
Lydia Shannon is a 23-year-old photographer. After finding out she has an 84%
chance of getting breast cancer (based on genetic testing), she wanted to do something
to make a difference. She told friends and family that if she raised $10,000, she would
shave her head and donate her hair. She created an online photography auction and
raffle called, F Stop Breast Cancer, which raised over $12,000; hence, her current
baldness.
Camp Phoenix: Kabul, Afghanistan
In a little over 40 days, Shamika Mitchell of Delta Detachment (82nd Financial
Management Company in Fort Bragg, North Carolina), PFC Michelle Redner and
SPC Erin Quinn of Bravo Company (186th BSB) planned a race in Camp Phoenix,
Afghanistan. On October 23, 6:30 AM, more than 300 people came out to run four
miles or walk two miles. They raised $3,000.
Bunco For Breast Cancer: Woodstock, IL
On October 17, the Crystal Lake Inn was buzzing with organizers and volunteers as
they set-up for Woodstock’s 6th Annual Bunco For Breast Cancer event. The first of
600 guests arrived early and by 1pm, 50 huge baskets had been raffled, the room was
filled to capacity and the Bunco started. It didn’t take long before $65,000 was raised!
The Woodstock group – founded in 2005 by Susan Martino and her daughters, Tracy
Noe and Laura Littner – has become the biggest and most successful group in the
history of Bunco For Breast Cancer. Susan and her daughters are all breast cancer
survivors and share an inspiring determination to support the Foundation’s mission.
The event has cumulatively generated over $260,000 for BCRF. Photo: Laura Martino
Littner, Tracy Martino Noe, Susan Martino, Walter Martino and Michelle Martino Mitchell
BCRF Leaders Council
Gail Hilson, Chairman
Roberta M. Amon
Jessie Araskog
Muffie Potter Aston
Anne H. Bass
Candice Bergen
Magda Bleier
Melinda Blinken
Katherine Bryan
Susan Payson Burke
Catherine Cahill
Wendy Carduner
Patty Cisneros
Norma Dana
Beth Rudin DeWoody
Barbaralee Diamonstein-Spielvogel
Robin Chandler Duke
HRH Princess Firyal
Marjorie Reed Gordon
Lorna Hyde Graev
Jamee Gregory
Audrey Gruss
Joanne de Guardiola
Candy Hamm
Mai Hallingby Harrison
Dina Merrill Hartley
Gale Hayman
Veronica Hearst
Marlene Hess
Karen M. Karp
Mariana Kaufman
Kitty Kempner
Eleanora Kennedy
Coco Kopelman
Jo Carole Lauder
Karen Lauder
Karen LeFrak
Wendy Vanderbilt Lehman
Memrie M. Lewis
Nicole Limbocker
Carol Mack
Hillie Mahoney
Ketty Maisonrouge
Grace T. Meigher
Liz Mezzacappa
Muffy Miller
Nancy Missett
Gigi Mortimer
Deborah Norville
Libby Pataki
Pat Patterson
Jean H. Pearman
Toni Peebler
Carroll Petrie
Pauline Pitt
Patricia Quick
Annette de la Renta
Patricia Rosenwald
Hilary Geary Ross
June Schorr
Christine Hearst Schwarzman
Jeanne Sorensen Siegel
Nancy Silverman
Anne Sitrick
Daisy Soros
Louise M. Sunshine
Felicia Taylor
Joan H. Tisch
Adrienne Vittadini
Barbara Walters
Patricia G. Warner
Thorunn Wathne
Harriet Weintraub
Saundra Whitney
Vivien Wyser-Pratte
Paula Zahn
Thank You
BCRF Advisory Board
Nestle Waters doubled its donation and presented a
$500,000 check to BCRF. Pictured: Robbie Franklin;
Kim Jeffery, President and CEO, Nestle Waters North
America; Myra Biblowit
On September 13, Kmart and breast
cancer survivor Jaclyn Smith (pictured
with Mark Snyder, Chief Marketing
Officer, Kmart) celebrated the 25th
Anniversary of their design collaboration. $1 of any purchase from the
limited-edition home and fashion
collection was donated to BCRF.
Thanks to Jerry Kohl and his wife Terri, Brighton
Collectibles is contributing 100% of the proceeds
from a special pink ribbon charm to BCRF. Enclosed
with the charm is a $20 check to BCRF. Customers mail
the check to BCRF. This novel campaign has been widely
successful and raised nearly $80,000 to date.
On October 25, Reed Krakoff hosted an
evening at his new NYC store to celebrate
BCRF, and honored the Foundation with a
gift of $25,000. Pictured: Co-hosts Gigi
Mortimer, Tory Burch, Reed Krakoff,
Evelyn Lauder and Perri Peltz.
Federico Lagrange of Northland (L) presented a
$30,000 check to Jaclyn Lee of BCRF (R) at the
BJ’s Wholesale Club in Miami. The donation was
made possible through Northland’s Drink to Pink
program, which BJ’s enthusiastically supported
in their May 2010 promotion.
On July 12, Key Food organized a golf
outing to raise $50,000 for BCRF.
Pictured is Dean Janeway, Chief Executive
Officer of Key Food Stores.
Arlene Adler
Roberta M. Amon
Melinda Blinken
Mary Bryant
Susan Payson Burke
Darlene Daggett
Rena Rowan Damone
Elisha Daniels
Ute Dugan, MD, PhD
Suzanne Elson
Stephanie Ginsberg
Amy P. Goldman, PhD
Barbara Goldsmith
Roslyn Goldstein
Marjorie Reed Gordon
Lorna Hyde Graev
Betsy S. Green
Bette-Ann Gwathmey
Lori Hall
Susan Hertog
Ronnie Heyman
Gail Hilson
Susan B. Hirschhorn
Jane Hertzmark Hudis
Robin J. Kemper
Rochelle Kivell
Sandra Krakoff
Elyse Lacher
Maralyn Lakin
Laura Lassman
Ellen Levine
Marisa Acocella Marchetto
Ellen Odoner, Esq.
Mary Alice Pappas
Winifred Gorlin Phillips
Jane Pontarelli
Patricia Quick
Katharine Rayner
Lynda Resnick
Wendi Rose
Patricia Rosenwald
Valerie Salembier
Suzanne Santry
Judith P. Schlager
Muriel Siebert
Anne Sitrick
Joanne Smith
Erana Stennett
Arlene Taub
Linda Waintrup
Cathy Weinroth
Harriet Weintraub
Candace King Weir
Nina Wexler
Sara Wolfensohn
Jacki Zehner
Rhonda S. Zinner
15
The Breast Cancer Research Foundation
60 East 56th Street, 8th Floor
New York, New York 10022
NON-PROFIT
US POSTAGE PAID
ADDRESS SERVICE REQUESTED
NEW YORK, NY
PRINTED ON RECYCLED PAPER
PERMIT NO. 2377
BCRF Board of Directors
Evelyn H. Lauder, Founder and Chairman
Myra J. Biblowit, President
Jeanette S. Wagner, Vice President
Deborah Krulewitch, Secretary and Treasurer
Carolee Friedlander
Kinga Lampert
Cynthia Lufkin
Carlyn S. McCaffrey, Esq.
Teruca Rullán
Josie Robertson, in memoriam
To Contact BCRF:
646.497.2600 / 866 FINDACURE
[email protected]
www.bcrfcure.org
Executive Board of Scientific Advisors
Scientific Advisory Committee
Chairman and Scientific Director
Larry Norton, MD
Chairman
Clifford Hudis, MD
Members
Nancy E. Davidson, MD
University of Pittsburgh Cancer Institute
Members
Patricia A. Ganz, MD
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
PHOTOS: Rob Rich
winter 2011
16
Peter Greenwald, MD, Dr.PH
National Cancer Institute
National Institutes of Health
Gabriel N. Hortobagyi, MD
University of Texas
2011 PINK Calendar
FEBRUARY
The Hot Pink Luncheon & Symposium
Monday, February 7
The Breakers, Palm Beach, FL
MARCH
Challenge of the Americas
Saturday, March 12
International Polo Club, Wellington, FL
Judy E. Garber, MD, MPH
Dana-Farber Cancer Institute
Lajos Pusztai, MD, D.Phil
University of Texas
Vered Stearns, MD
Johns Hopkins University School of Medicine
The Boston Hot Pink Party
Tuesday, May 17
Museum of Fine Arts, Boston
JULY
BCRF Golf Classic
Monday, July 18 Liberty National Golf Course, Jersey City, NJ
Boston Hot Pink Party Kick-off Event Wednesday, March 16 David Yurman Copley Place, Boston
AUGUST
Estée Lauder’s “Play for Pink” Golf & Tennis Classic
Monday, August 15
Old Westbury Country Club, Old Westbury, NY
APRIL
The Hot Pink Party with Sir Elton John
Thursday, April 14
The Waldorf=Astoria, NYC
OCTOBER
Pink Promises Luncheon and Symposium
Wednesday, October 12
Long Island, NY
MAY
Chappaqua’s A Cure in Our Lifetime Breakfast
Friday, May 13
Trump National Golf Club, Briarcliff Manor, NY
Symposium and Annual Awards Luncheon
Wednesday, October 26
The Waldorf=Astoria, NYC

BCRF Pink Press Winter 2011

Transcription

Similar documents

Marketplace of Homes Marketplace of Homes

experienced. focused. evolving. just like you.

Inglês

Fall 2007 - A.T. Still University

international conference places on the edge creating a sense of

Saturday, May 22, 2004, Saskatoon Star Phoenix

9:30 am - Greater Little Zion Baptist Church

Sientra Silicone Gel Breast Implants Quick Facts About Breast

Corporate Partnership Opportunities

Annual Report - Sisters Network Inc.